These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 32185791)

  • 1. Advances in the Treatment of Drug-Resistant Pediatric Epilepsy.
    Gonzalez-Giraldo E; Sullivan JE
    Semin Neurol; 2020 Apr; 40(2):257-262. PubMed ID: 32185791
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Advances and guidance in the treatment of drug-resistant epilepsy: a review by the Andalusian Epilepsy Society of the new drugs cenobamate, fenfluramine and cannabidiol].
    Arenas-Cabrera C; Cabezudo-García P; Calvo-Medina R; Galeano-Bilbao B; Martínez-Agredano P; Ruiz-Giménez J; Rodríguez-Uranga JJ; Quiroga-Subirana P
    Rev Neurol; 2024 Sep; 79(6):161-173. PubMed ID: 39267402
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term safety and efficacy of cannabidiol in children and adults with treatment resistant Lennox-Gastaut syndrome or Dravet syndrome: Expanded access program results.
    Laux LC; Bebin EM; Checketts D; Chez M; Flamini R; Marsh ED; Miller I; Nichol K; Park Y; Segal E; Seltzer L; Szaflarski JP; Thiele EA; Weinstock A;
    Epilepsy Res; 2019 Aug; 154():13-20. PubMed ID: 31022635
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cannabidiol as adjunctive treatment of seizures associated with Lennox-Gastaut syndrome and Dravet syndrome.
    Lattanzi S; Trinka E; Russo E; Striano P; Citraro R; Silvestrini M; Brigo F
    Drugs Today (Barc); 2019 Mar; 55(3):177-196. PubMed ID: 30938373
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cannabidiol in patients with treatment-resistant epilepsy: an open-label interventional trial.
    Devinsky O; Marsh E; Friedman D; Thiele E; Laux L; Sullivan J; Miller I; Flamini R; Wilfong A; Filloux F; Wong M; Tilton N; Bruno P; Bluvstein J; Hedlund J; Kamens R; Maclean J; Nangia S; Singhal NS; Wilson CA; Patel A; Cilio MR
    Lancet Neurol; 2016 Mar; 15(3):270-8. PubMed ID: 26724101
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Therapeutic and clinical foundations of cannabidiol therapy for difficult-to-treat seizures in children and adults with refractory epilepsies.
    Reddy DS
    Exp Neurol; 2023 Jan; 359():114237. PubMed ID: 36206806
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel therapeutic options for Dravet and Lennox-Gastaut syndrome.
    Verrotti A; Striano P
    Expert Rev Neurother; 2021 Nov; 21(11):1191-1194. PubMed ID: 33297778
    [No Abstract]   [Full Text] [Related]  

  • 8. Thrombocytopenia in pediatric patients on concurrent cannabidiol and valproic acid.
    McNamara NA; Dang LT; Sturza J; Ziobro JM; Fedak Romanowski EM; Smith GC; Joshi SM; Leber SM; Carlson M; Robertson P; Shellhaas RA
    Epilepsia; 2020 Aug; 61(8):e85-e89. PubMed ID: 32614070
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cannabidiol for epilepsy: trying to see through the haze.
    Detyniecki K; Hirsch LJ
    Lancet Neurol; 2016 Mar; 15(3):235-7. PubMed ID: 26776916
    [No Abstract]   [Full Text] [Related]  

  • 10. Perceived efficacy of cannabidiol-enriched cannabis extracts for treatment of pediatric epilepsy: A potential role for infantile spasms and Lennox-Gastaut syndrome.
    Hussain SA; Zhou R; Jacobson C; Weng J; Cheng E; Lay J; Hung P; Lerner JT; Sankar R
    Epilepsy Behav; 2015 Jun; 47():138-41. PubMed ID: 25935511
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New therapeutic approach in Dravet syndrome and Lennox-Gastaut syndrome with cannabidiol.
    Villanueva V; Carreño-Martínez M; Gil Nagel-Rein A; López-González FJ
    Rev Neurol; 2021 Apr; 72(S01):S1-S10. PubMed ID: 33908026
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cannabinoids in treatment-resistant epilepsy: A review.
    O'Connell BK; Gloss D; Devinsky O
    Epilepsy Behav; 2017 May; 70(Pt B):341-348. PubMed ID: 28188044
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Severe myoclonic epilepsy in infancy (Dravet's syndrome). Its nosological characteristics and therapeutic aspects].
    Nieto Barrera M; Candau Fernandez Mensaque R; Nieto Jiménez M
    Rev Neurol; 2003 Jul 1-15; 37(1):64-8. PubMed ID: 12861512
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cannabidiol Therapy for Refractory Epilepsy and Seizure Disorders.
    Golub V; Reddy DS
    Adv Exp Med Biol; 2021; 1264():93-110. PubMed ID: 33332006
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The proposed mechanisms of action of CBD in epilepsy.
    Gray RA; Whalley BJ
    Epileptic Disord; 2020 Jan; 22(S1):10-15. PubMed ID: 32053110
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Emerging Antiepileptic Drugs for Severe Pediatric Epilepsies.
    Mudigoudar B; Weatherspoon S; Wheless JW
    Semin Pediatr Neurol; 2016 May; 23(2):167-79. PubMed ID: 27544474
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Parental reporting of response to oral cannabis extracts for treatment of refractory epilepsy.
    Press CA; Knupp KG; Chapman KE
    Epilepsy Behav; 2015 Apr; 45():49-52. PubMed ID: 25845492
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cannabis for the Treatment of Epilepsy: an Update.
    Gaston TE; Szaflarski JP
    Curr Neurol Neurosci Rep; 2018 Sep; 18(11):73. PubMed ID: 30194563
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of cannabinoids in epilepsy treatment: a critical review of efficacy results from clinical trials.
    Nabbout R; Thiele EA
    Epileptic Disord; 2020 Jan; 22(S1):23-28. PubMed ID: 31916540
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Epilepsy and cannabidiol: a guide to treatment.
    Arzimanoglou A; Brandl U; Cross JH; Gil-Nagel A; Lagae L; Landmark CJ; Specchio N; Nabbout R; Thiele EA; Gubbay O; The Cannabinoids International Experts Panel ;
    Epileptic Disord; 2020 Feb; 22(1):1-14. PubMed ID: 32096470
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.